“BD’s strong revenue and EPS growth reflect solid execution across the company and positive momentum to start fiscal 2021,” said Tom Polen, CEO and president of BD. “While the market continues to be dynamic with the COVID-19 pandemic, BD has emerged as an essential partner to help the world respond to the COVID-19 pandemic from diagnostics to devices used in treatment to injection devices for vaccines and real-time surveillance and reporting. I’m proud of the worldwide BD team for their COVID-19 response efforts and support of healthcare providers around the world. We are focused on driving our BD 2025 Grow-Simplify-Empower strategic initiatives which include bringing new and exciting innovations to the health care markets, expanding access globally and creating value for our shareholders. To that end, we continue to make solid progress.”

—Tom Polen, CEO and President

1. Reflects currency-neutral revenue growth for the three-month period ended December 31, 2020 compared to the comparable period in 2019 on a year-over-year basis.
2. Reflects adjusted non-GAAP earnings per share, which excludes, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, restructuring and transaction costs.
3. Represents the number of BD Veritor™ analyzers added since the beginning of the COVID-19 pandemic.

These materials include non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found in our earnings release including the financial schedules and financial supplements, posted on the “Investors” section of the BD.com website. This document contains forward-looking statements and it’s possible that actual results could differ from our expectations. Factors that could cause such differences appear in our first quarter of fiscal 2021 earnings release furnished as an exhibit to the Form 8-K that BD filed on February 4, 2021 with the SEC, and in our recent SEC filings.

Q1 FY21 financials

<table>
<thead>
<tr>
<th>Financial Measure</th>
<th>Growth/Yield</th>
<th>Adjusted EPS</th>
<th>Growth/Yield</th>
</tr>
</thead>
<tbody>
<tr>
<td>FXN revenue growth</td>
<td>24.3%</td>
<td>Adjusted EPS</td>
<td>$4.55</td>
</tr>
</tbody>
</table>

Commitments for over 1B injection devices to enable COVID-19 vaccinations

Resilience of the core business

Acuity, demand for critical need products, and procedure resiliency drove revenue growth

BD Medical

FXN revenue growth | 6.9% |

BD Interventional

FXN revenue growth | 5.0% |